| Name | Title | Contact Details |
|---|
JustRight Surgical was founded in order to address a previously unmet need: the ability for pediatric surgeons to safely and effectively perform minimally invasive surgery in pediatric patients from neonate to teenager. Up until 2010, the only devices available for use in pediatric surgery were high-powered adult-sized instruments, which cause access issues and visualization problems during procedures.
Bonnie Bell is a Westlake, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
David Thompson Health Region is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. David Thompson Health Region is based in Norglenwold, AB. You can find more information on David Thompson Health Region at www.dthr.ab.ca
Doctors Hospital Parkway + Tidwell is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Houston, TX. To find more information about Doctors Hospital Parkway + Tidwell, please visit www.dhthou.com
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.